2198-9788

Drugs - Real World Outcomes

Springer-Verlag

View prefix report (10.1007)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 549 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact549 DOIs
2

Attach ORCID iDs across 205 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact205 DOIs
3

Deposit reference lists for 28 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact28 DOIs

DOIs for this ISSN

Showing the top 5 of 555 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Context and Considerations for Use of Two Japanese Real-Worl… (10.1007/s40801-022-00296-5)
Abstract ORCID
100.85 103
2 Adverse Drug Events and Medication Errors in African Hospita… (10.1007/s40801-017-0125-6)
Abstract ORCID
96.47 84
3 The First Eastern Mediterranean Region/Arab Countries Meetin… (10.1007/s40801-015-0015-8)
Abstract References ORCID
94.15 17
4 Prevalence of Central Nervous System Polypharmacy and Associ… (10.1007/s40801-015-0055-0)
Abstract ORCID
85.80 51
5 Characterisation of Drug-Related Problems and Associated Fac… (10.1007/s40801-017-0108-7)
Abstract ORCID
85.38 50
6 Adverse Drug Reaction Reporting Pattern in Turkey: Analysis… (10.1007/s40801-015-0054-1)
Abstract ORCID
82.17 43
7 Treatment of Acute Osteomyelitis with Once-Weekly Oritavanci… (10.1007/s40801-020-00195-7)
Abstract ORCID
80.64 40
8 Clinical Outcomes with First-Line Chemotherapy in a Large Re… (10.1007/s40801-018-0137-x)
Abstract ORCID
80.10 39
9 Risk Factors Associated with the Requirement for Pharmaceuti… (10.1007/s40801-016-0083-4)
Abstract ORCID
79.55 38
10 Correlation of Incident Potentially Inappropriate Medication… (10.1007/s40801-015-0035-4)
Abstract ORCID
78.41 36
11 Traditional Anticoagulants and Hair Loss: A Role for Direct… (10.1007/s40801-015-0056-z)
Abstract ORCID
78.41 36
12 Comparing Biologic Cost Per Treated Patient Across Indicatio… (10.1007/s40801-016-0093-2)
Abstract ORCID
76.57 33
13 Medicines Management, Medication Errors and Adverse Medicati… (10.1007/s40801-016-0065-6)
Abstract ORCID
75.93 32
14 Severe Cutaneous Adverse Drug Reactions Associated with Allo… (10.1007/s40801-019-00174-7)
Abstract ORCID
75.93 32
15 Drug-Induced Subacute Cutaneous Lupus Erythematosus Associat… (10.1007/s40801-016-0067-4)
Abstract ORCID
74.57 30
16 The Risk of Specific Congenital Anomalies in Relation to New… (10.1007/s40801-016-0078-1)
Abstract ORCID
73.86 29
17 Real-World Analysis of Switching Patients with Schizophrenia… (10.1007/s40801-019-00172-9)
Abstract ORCID
72.36 27
18 Clinical Outcomes and Economic Impact of Oritavancin for Gra… (10.1007/s40801-020-00192-w)
Abstract ORCID
72.36 27
19 Real-World Use of Oritavancin for the Treatment of Osteomyel… (10.1007/s40801-020-00194-8)
Abstract ORCID
72.36 27
20 Costs and Resource Utilization Among Medicaid Patients with… (10.1007/s40801-015-0043-4)
Abstract ORCID
71.57 26
21 HER2-Positive Metastatic Breast Cancer Patients Receiving Pe… (10.1007/s40801-016-0102-5)
Abstract ORCID
71.57 26
22 Type and Frequency of Opioid Pain Medications Returned for D… (10.1007/s40801-015-0019-4)
Abstract ORCID
70.75 25
23 Drug-Related Problems Identified in a Sample of Portuguese I… (10.1007/s40801-016-0061-x)
Abstract ORCID
70.75 25
24 Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK) Re… (10.1007/s40801-016-0064-7)
Abstract ORCID
69.90 24
25 PEARL: A Non-interventional Study of Real-World Alirocumab U… (10.1007/s40801-019-0158-0)
Abstract ORCID
69.01 23
26 A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimat… (10.1007/s40801-020-00188-6)
Abstract ORCID
69.01 23
27 Associations of Potentially Inappropriate Medicine Use with… (10.1007/s40801-015-0020-y)
Abstract ORCID
68.09 22
28 Prevalence of Drug-Related Emergency Department Visits at a… (10.1007/s40801-015-0045-2)
Abstract ORCID
68.09 22
29 An Evaluation of “Drug Ineffective” Postmarketing Reports in… (10.1007/s40801-018-0131-3)
Abstract ORCID
68.09 22
30 Safety and Tolerability of the Potassium Binder Patiromer Fr… (10.1007/s40801-021-00254-7)
Abstract ORCID
67.12 21
31 Economic Burden of Herpes Zoster and Post-Herpetic Neuralgia… (10.1007/s40801-017-0119-4)
Abstract ORCID
66.11 20
32 Medication Adherence and Healthcare Costs Among Patients wit… (10.1007/s40801-020-00183-x)
Abstract ORCID
66.11 20
33 Patterns of Treatment Sequences in Chemotherapy and Targeted… (10.1007/s40801-015-0059-9)
Abstract ORCID
65.05 19
34 Seasonal and Geographic Variation in Adverse Event Reporting (10.1007/s40801-016-0081-6)
Abstract ORCID
65.05 19
35 Impact of Pediatric Acute Otitis Media on Child and Parental… (10.1007/s40801-016-0099-9)
Abstract ORCID
65.05 19
36 Polypharmacy Among the Elderly in a List-Patient System (10.1007/s40801-015-0036-3)
Abstract ORCID
62.76 17
37 Drug Utilisation Patterns in Children Admitted to a Paediatr… (10.1007/s40801-015-0049-y)
Abstract ORCID
62.76 17
38 Inadequate Sedation During Therapeutic Paralysis: Use of Bis… (10.1007/s40801-016-0076-3)
Abstract ORCID
62.76 17
39 Characterization of Stevens–Johnson Syndrome and Toxic Epide… (10.1007/s40801-017-0105-x)
Abstract ORCID
62.76 17
40 Prevalence and Variability in Medications Contributing to Po… (10.1007/s40801-017-0121-x)
Abstract ORCID
62.76 17
41 General Practitioners’ Prescribing Patterns at Primary Healt… (10.1007/s40801-016-0087-0)
Abstract ORCID
61.52 16
42 Evaluating the Safety of Medication Exposures During Pregnan… (10.1007/s40801-017-0114-9)
Abstract ORCID
61.52 16
43 Retrospective Observational Study of ALK-Inhibitor Therapy S… (10.1007/s40801-020-00207-6)
Abstract ORCID
61.52 16
44 Impact of "time zero" of Follow-Up Settings in a Comparative… (10.1007/s40801-022-00343-1)
Abstract ORCID
61.52 16
45 Intravenous Immunoglobulin (IVIg) Utilization in Immune Thro… (10.1007/s40801-015-0009-6)
Abstract ORCID
60.21 15
46 Use of Medicines with Anticholinergic and Sedative Effect Be… (10.1007/s40801-015-0012-y)
Abstract ORCID
60.21 15
47 Physician and Pharmacist Understanding of the Risk of Urinar… (10.1007/s40801-015-0042-5)
Abstract ORCID
60.21 15
48 Potentially Inappropriate Medications in the Elderly in Kore… (10.1007/s40801-015-0046-1)
Abstract ORCID
60.21 15
49 Patients’ Willingness to Take Multiple-Tablet Antiretroviral… (10.1007/s40801-016-0070-9)
Abstract ORCID
60.21 15
50 The Clinical and Economic Impact of the V-Go® Disposable Ins… (10.1007/s40801-016-0075-4)
Abstract ORCID
60.21 15